Discontinuation of non-anti-TNF drugs for rheumatoid arthritis in interventional versus observational studies: a systematic review and meta-analysis
Although randomized controlled trials (RCTs) are the gold standard for the assessment of clinical outcomes, long-term extension trials (LTEs) and observational cohorts may help generate evidence. Our goal was to compare the discontinuation rates of abatacept, rituximab, and tocilizumab in rheumatoid arthritis (RA) reported in different study designs.
A systematic review was conducted with searches in PubMed, Scopus, and the Cochrane Library, plus a manual search, for RCTs, LTEs, and observational cohorts reporting discontinuation rates by any of three causes (all-cause, inefficacy, adverse events). Meta-analyses with sensitivity analyses and meta-regressions were conducted.
Of the 111 studies included, 74 were RCTs (n = 55) or LTEs (n = 17) reporting data on abatacept (n = 33), rituximab (n = 10), and tocilizumab (n = 31) and 37 were observational cohort studies (abatacept = 11, rituximab = 8, tocilizumab = 18). The follow-up duration did not differ among the study designs. Discontinuation rates were similar among the drugs but varied among the study designs. Discontinuation rates were significantly higher in cohort studies than those in interventional studies for the three drugs. Sensitivity analyses could not identify patient characteristics associated with these differences. Meta-regression analyses demonstrated no correlation between study follow-up duration and discontinuation rates.
The discontinuation rates reported for non-anti-TNF drugs varied relative to the study design in which they were investigated. Regulatory agencies, price-setting entities, and evidence-gathering researchers should consider the effect of the real-life environment in their decisions and conclusions.
KeywordsRheumatoid arthritis Statistics and study design Evidence-based medicine Medication Adherence
AW, RP, FFL, and FST designed the study and wrote the protocol. LMS, LPL, VLF, HHB, TP, and AGSA screened and abstracted publications. LMS, LPL, VLF, and HHB evaluated methodological quality. FST, AW, and FFL statistically analyzed data. FST and FFL wrote the manuscript, with editorial contributions from LMS, LPL, VLF, HHB, TP, AGSA, AW, and RP. All authors reviewed the manuscript for accuracy and scientific content.
This work was supported by Fellow of the Brazilian National Council of Scientific and Technological Research—CNPq (grant Universal 14/2014-442095/2014-7).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 8.Ankarfeldt MZ, Adalsteinsson E, Groenwold RH, Ali MS, Klungel OH (2017) A systematic literature review on the efficacy-effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs. Clin Epidemiol 9:41–51. https://doi.org/10.2147/CLEP.S121991 CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73(3):492–509. https://doi.org/10.1136/annrheumdis-2013-204573 CrossRefPubMedGoogle Scholar
- 12.Johnston SS, McMorrow D, Farr AM, Juneau P, Ogale S (2015) Comparison of biologic disease-modifying antirheumatic drug therapy persistence between biologics among rheumatoid arthritis patients switching from another biologic. Rheumatol Ther 2(1):59–71. https://doi.org/10.1007/s40744-014-0006-3 CrossRefPubMedGoogle Scholar
- 13.Remy A, Avouac J, Gossec L, Combe B (2011) Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. Clin Exp Rheumatol 29(1):96–103PubMedGoogle Scholar
- 14.Souto A, Maneiro JR, Gomez-Reino JJ (2016) Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology 55(3):523–534. https://doi.org/10.1093/rheumatology/kev374 CrossRefPubMedGoogle Scholar
- 16.Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P, Gossec L, Landewe R, Smolen JS, Buch MH (2014) Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 73(3):516–528. https://doi.org/10.1136/annrheumdis-2013-204577 CrossRefPubMedGoogle Scholar
- 20.Buch MH, Silva-Fernandez L, Carmona L, Aletaha D, Christensen R, Combe B, Emery P, Ferraccioli G, Guillemin F, Kvien TK, Landewe R, Pavelka K, Saag K, Smolen JS, Symmons D, van der Heijde D, Welling J, Wells G, Westhovens R, Zink A, Boers M, European League Against R (2015) Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. Ann Rheum Dis 74(6):963–969. https://doi.org/10.1136/annrheumdis-2013-204948 CrossRefPubMedGoogle Scholar
- 21.Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. CochraneGoogle Scholar
- 22.Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical research ed) 339:339. https://doi.org/10.1136/bmj.b2700 CrossRefGoogle Scholar
- 24.Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P (2013) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. In: ed.Google Scholar
- 26.Ramiro S, Landewe R, van der Heijde D, Harrison D, Collier D, Michaud K (2015) Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors? RMD Open 1(1):e000155. https://doi.org/10.1136/rmdopen-2015-000155 CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Tarp S, Furst DE, Dossing A, Ostergaard M, Lorenzen T, Hansen MS, Singh JA, Choy EH, Boers M, Suarez-Almazor ME, Kristensen LE, Bliddal H, Christensen R (2016) Defining the optimal biological monotherapy in rheumatoid arthritis: a systematic review and meta-analysis of randomised trials. Semin Arthritis Rheum DOI 46:699–708. https://doi.org/10.1016/j.semarthrit.2016.09.003 CrossRefGoogle Scholar
- 28.Gottenberg JE, Brocq O, Perdriger A, Lassoued S, Berthelot JM, Wendling D, Euller-Ziegler L, Soubrier M, Richez C, Fautrel B, Constantin AL, Mariette X, Morel J, Gilson M, Cormier G, Salmon JH, Rist S, Liote F, Marotte H, Bonnet C, Marcelli C, Sellam J, Meyer O, Solau-Gervais E, Guis S, Ziza JM, Zarnitsky C, Chary-Valckenaere I, Vittecoq O, Saraux A, Pers YM, Gayraud M, Bolla G, Claudepierre P, Ardizzone M, Dernis E, Breban MA, Fain O, Balblanc JC, Aberkane O, Vazel M, Back C, Candon S, Chatenoud L, Perrodeau E, Sibilia J, Ravaud P (2016) Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial. JAMA 316(11):1172–1180. https://doi.org/10.1001/jama.2016.13512 CrossRefPubMedGoogle Scholar
- 29.Lee YH, Bae SC (2016) Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials. Int J Rheum Dis 19(11):1103–1111. https://doi.org/10.1111/1756-185X.12822 CrossRefPubMedGoogle Scholar
- 35.Kardos P, Worsley S, Singh D, Roman-Rodriguez M, Newby DE, Mullerova H (2016) Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD. Int J Chron Obstruct Pulmon Dis 11:2885–2895. https://doi.org/10.2147/COPD.S118867 CrossRefPubMedPubMedCentralGoogle Scholar
- 46.Ebina K, Hashimoto M, Yamamoto W, Ohnishi A, Kabata D, Hirano T, Hara R, Katayama M, Yoshida S, Nagai K, Son Y, Amuro H, Akashi K, Fujimura T, Hirao M, Yamamoto K, Shintani A, Kumanogoh A, Yoshikawa H (2018) Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis—the ANSWER cohort study. PLoS One 13(3):e0194130. https://doi.org/10.1371/journal.pone.0194130 CrossRefPubMedPubMedCentralGoogle Scholar
- 50.Zupnick A (2017) The impact of faster drug approvals on oncology clinical trial design. In: Strategy O (Ed.) Applied clinical trials edGoogle Scholar
- 54.Woolacott N, Corbett M, Jones-Diette J, Hodgson R (2017) Methodological challenges identified for the evaluation of clinical effectiveness in the context of accelerated regulatory approval: an overview. J Clin Epidemiol DOI 90:108–118. https://doi.org/10.1016/j.jclinepi.2017.07.002 CrossRefGoogle Scholar